Servier’s €15 mn bet on single-pill platform in India

Listen to this article in summarized format

French pharmaceutical group Servier is deepening its strategic footprint in India with the launch of a global platform dedicated to single-pill combinations (SPCs) for cardiometabolic and venous diseases, backed by an investment of around €15 million in 2026.

SPCs can improve treatment adherence by simplifying multi-pill regimens into a single daily dose, potentially leading to better long-term outcomes.

The platform, named GATINN, will be based in India and act as a global coordination hub for developing, manufacturing and exporting SPCs to international markets where patient adherence to chronic therapies remains a major challenge, a top company official said. It is Servier’s first such global platform and reflects a broader shift towards leveraging India’s development and manufacturing capabilities alongside French R&D and quality expertise.

These include regions across Asia, Latin America, Africa and the Middle East. The first international product launch from the platform is expected in Q2 2027.

“Servier Global and Servier India could be the best combination possible. India has bright scientists, bioequivalence experts and what India can bring in terms of manufacturing, scale, expertise and quality will be of great value,” said Charlotte Marmousez, executive vice president-corporate strategy & transformation at Servier.

“This is first such platform for Servier, which will coordinate on behalf of the global Servier teams from research and manufacturing, based in the headquarters in France,” she added.

Servier India is a part of the Servier group operating in more than 130 countries and focuses on key therapeutic areas of cardiometabolism, venous diseases and oncology.

Servier will collaborate with selected Indian contract development and manufacturing organisations (CDMOs) for finished dosage manufacturing, while continuing to source active pharmaceutical ingredients from its own production facilities, where it is the originator. The platform integrates development, supply chain and quality oversight under a single India-based structure.

The company expects to have around five SPCs by the end of 2026, followed by the addition of approximately one new product annually until 2030, creating a steady pipeline aligned with its long-term growth ambitions, said Kshitij Panse, chief operating officer, GATINN. Three of these are already in development, which are in the area of diabetes, and two more planned by end of the year will be in the cardiovascular metabolic domain.

Bradley Lloyd, managing director-APAC at Servier, said India is an important place for the company right now. “There are two things we need to look at when it comes to India. One is the role India can play in terms of generating revenues domestically and second dimension is the role India can play in the broader strategy of our group. There are a few countries in the world and India is starting to be one of them where we can have conversations in both dimensions.”

The company estimates a revenue of €500 million from the GATINN platform by 2030, a top official said.

Leading Mumbai-based cardiologist Hemant Thakkar said, “If you have a single pill which will attenuate the disease, treat the symptoms and put a good mindset in the patient to adhere to, it will be a big positive”.

Non-adherence is a big problem and is here to stay, said top endocrinologist Shashank Joshi. “In silent diseases like heart diseases or diabetes or obesity, we need combination pills with right dosing, etc. GATINN platform has a key role to play in this. Combination allows us convenience, cost-effectiveness and compliance. And all these three will control complications.”

Answering a query on increasing competition in the cardiometabolic space, Aurelien Breton, managing director, Servier India, said: “We have our molecules that are extremely powerful. Our role is to carry on supporting physicians to spread the knowledge and make sure the science is well understood as well as to make sure that quality is a key differentiator.”